Group 1 - The core point of the news is that Aomei Medical's stock price increased by 5.2% to 11.13 CNY per share, with a trading volume of 94.02 million CNY and a turnover rate of 1.92%, resulting in a total market capitalization of 7.048 billion CNY [1] - Aomei Medical, established on July 24, 2002, and listed on March 11, 2019, specializes in the research, production, and sales of disposable medical consumables, particularly medical dressings [1] - The main revenue composition of Aomei Medical includes surgical and wound care at 79.19%, other categories at 6.62%, infection protection at 5.05%, advanced dressings at 4.68%, and hygiene care at 4.46% [1] Group 2 - Among the top ten circulating shareholders of Aomei Medical, a fund under Yongying Fund ranks first, while the Medical Device ETF (159883) entered the top ten shareholders in the third quarter, holding 1.5656 million shares, which is 0.35% of the circulating shares [2] - The Medical Device ETF (159883) was established on April 22, 2021, with a latest scale of 3.677 billion CNY, and has achieved a year-to-date return of 5.1%, ranking 2041 out of 5564 in its category [2] - The fund manager of the Medical Device ETF is Shu Kefa, who has been in the position for 2 years and 178 days, with a total fund asset size of 5.205 billion CNY, achieving a best return of 103.17% and a worst return of -30.27% during his tenure [3]

Group 1 - The core point of the news is that Aomei Medical's stock price dropped by 5% to 12.16 yuan per share, with a trading volume of 193 million yuan and a turnover rate of 3.47%, resulting in a total market capitalization of 7.701 billion yuan [1] - Aomei Medical, established on July 24, 2002, and listed on March 11, 2019, specializes in the research, production, and sales of disposable medical consumables, particularly medical dressings [1] - The main revenue composition of Aomei Medical includes surgical and wound care at 79.19%, other categories at 6.62%, infection protection at 5.05%, advanced dressings at 4.68%, and hygiene care at 4.46% [1] Group 2 - Among the top ten circulating shareholders of Aomei Medical, a fund under Yongying Fund is included, and the Medical Device ETF (159883) entered the top ten shareholders in the third quarter, holding 1.5656 million shares, which accounts for 0.35% of the circulating shares [2] - The Medical Device ETF (159883) was established on April 22, 2021, with a latest scale of 3.677 billion yuan, and has achieved a year-to-date return of 8.42%, ranking 1994 out of 5549 in its category [2] - The fund has a one-year return of 14.06%, ranking 3672 out of 4285, and has experienced a cumulative loss of 47.1% since its inception [2] Group 3 - The fund manager of the Medical Device ETF (159883) is Shu Kefa, who has been in the position for 2 years and 169 days, managing a total fund size of 5.205 billion yuan [3] - During the tenure of the fund manager, the best fund return was 103.17%, while the worst return was -30.27% [3]

Company Overview - Aomei Medical is located in Zhijiang, Hubei Province, and was established on July 24, 2002. The company went public on March 11, 2019. Its main business involves the research, production, and sales of disposable medical consumables, including medical dressings [1]. - The revenue composition of Aomei Medical includes: surgical and wound care (79.19%), other categories (6.62%), infection protection (5.05%), advanced dressings (4.68%), and hygiene care (4.46%) [1]. Financial Performance - As of September 30, 2025, Aomei Medical achieved a revenue of 2.597 billion yuan, representing a year-on-year growth of 5.98%. The net profit attributable to the parent company was 349 million yuan, reflecting a year-on-year increase of 31.54% [2]. - Since its A-share listing, Aomei Medical has distributed a total of 1.099 billion yuan in dividends, with 91.913 million yuan distributed over the past three years [3]. Stock Performance - On January 8, Aomei Medical's stock price increased by 2.32%, reaching 11.46 yuan per share, with a trading volume of 50.793 million yuan and a turnover rate of 1.00%. The total market capitalization is 7.257 billion yuan [1]. - Year-to-date, Aomei Medical's stock has risen by 4.95%, with a 5-day increase of 5.04%, a 20-day increase of 0.79%, and a 60-day increase of 18.76% [1]. Shareholder Information - As of September 30, 2025, Aomei Medical had 37,800 shareholders, an increase of 0.71% from the previous period. The average number of circulating shares per person decreased by 0.71% to 11,965 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fifth largest, holding 17.9166 million shares, an increase of 5.5221 million shares from the previous period. The Medical Device ETF (159883) is the tenth largest shareholder, holding 1.5656 million shares as a new shareholder [3].

Group 1 - The core viewpoint of the news is that Aomei Medical has shown a mixed performance in its stock price and financial results, with a slight increase in stock price recently but a decline over the past few trading days [1][2]. - As of January 5, Aomei Medical's stock price increased by 2.01% to 11.14 CNY per share, with a market capitalization of 7.055 billion CNY [1]. - The company reported a revenue of 2.597 billion CNY for the first nine months of 2025, representing a year-on-year growth of 5.98%, and a net profit of 349 million CNY, which is a 31.54% increase compared to the previous year [2]. Group 2 - Aomei Medical's main business involves the research, production, and sales of disposable medical consumables, with the revenue composition being 79.19% from surgical and wound care, 6.62% from other categories, 5.05% from infection protection, 4.68% from advanced dressings, and 4.46% from hygiene care [1]. - The company has distributed a total of 1.099 billion CNY in dividends since its A-share listing, with 91.913 million CNY distributed over the past three years [3]. - As of September 30, 2025, the number of shareholders increased to 37,800, with an average of 11,965 circulating shares per person, a decrease of 0.71% [2][3].

Group 1 - The core viewpoint of the news is that Aomei Medical's stock has increased by 5.1%, reaching a price of 13.20 yuan per share, with a trading volume of 268 million yuan and a turnover rate of 4.60%, resulting in a total market capitalization of 8.359 billion yuan [1] - Aomei Medical, established on July 24, 2002, and listed on March 11, 2019, specializes in the research, production, and sales of disposable medical consumables, particularly medical dressings [1] - The main revenue composition of Aomei Medical includes surgical and wound care at 79.19%, other categories at 6.62%, infection protection at 5.05%, advanced dressings at 4.68%, and hygiene care at 4.46% [1] Group 2 - Among the top ten circulating shareholders of Aomei Medical, a fund under Yongying Fund ranks first, while the Medical Device ETF (159883) entered the top ten shareholders in the third quarter, holding 1.5656 million shares, which accounts for 0.35% of the circulating shares [2] - The Medical Device ETF (159883) was established on April 22, 2021, with a latest scale of 4.73 billion yuan, showing a year-to-date return of 9.53% and a one-year loss of 1.36% [2] - The fund manager of the Medical Device ETF is Shu Kefa, who has a cumulative tenure of 2 years and 92 days, with the fund's total asset scale at 6.282 billion yuan [3]

Core Viewpoint - Aomei Medical has successfully executed its share repurchase plan, exceeding the minimum funding requirement and demonstrating commitment to shareholder value [1][3]. Repurchase Plan Background - Aomei Medical's board approved a share repurchase plan on January 20, 2025, intending to use self-owned funds and special loan funds for stock repurchase, aimed at employee stock ownership plans [2]. - The repurchase price ceiling is set at 11.00 CNY per share, with a total funding range of no less than 50 million CNY and no more than 100 million CNY, to be completed within 12 months [2]. Repurchase Implementation Progress - As of October 31, 2025, Aomei Medical has repurchased 5.3062 million shares, representing 0.8379% of the total share capital, at an average price of 10.05 CNY per share, with a total expenditure of 50.6186 million CNY [3]. - The highest transaction price recorded was 10.05 CNY per share, and the lowest was 8.33 CNY per share, both below the set ceiling price [3]. Future Plans - Aomei Medical plans to continue its share repurchase according to market conditions within the remaining timeframe, adhering to relevant regulations and ensuring timely information disclosure [4].

Group 1 - The core viewpoint of the news highlights the current stock performance and valuation metrics of Aomei Medical, indicating a low PE ratio compared to the industry average [1] - As of June 9, Aomei Medical's stock closed at 8.89 yuan, with a PE ratio of 15.58, marking a new low in 43 days, and a total market capitalization of 5.63 billion yuan [1] - The medical device industry has an average PE ratio of 50.64, with Aomei Medical ranking 37th among its peers [1] Group 2 - Aomei Medical specializes in the research, production, and sales of medical consumables, disposable medical devices, infection protection products, and home care products [2] - The company has received multiple accolades, including being listed among the top 100 private manufacturing enterprises in Hubei and recognized for its intelligent manufacturing projects [2] - In the latest quarterly report for Q1 2025, Aomei Medical reported a revenue of 759 million yuan, a year-on-year increase of 1.64%, and a net profit of 86.5 million yuan, reflecting a year-on-year decrease of 7.86% [3]

Core Viewpoint - The legal opinion provided by Beijing Deheng (Nanjing) Law Firm confirms the legality and validity of the procedures, participants, and voting results of the 2024 Annual General Meeting of Aomei Medical Supplies Co., Ltd. [1][10] Group 1: Meeting Procedures - The third meeting of the board of directors approved the proposal to convene the annual general meeting on April 24, 2025 [2] - The meeting was postponed to June 4, 2025, while the record date for shareholding remained unchanged on May 26, 2025 [3][4] - The meeting was conducted with a combination of on-site voting and online voting, adhering to the previously disclosed arrangements [4] Group 2: Participant Qualifications - A total of 232 shareholders or their proxies attended the meeting, representing 13,622,310 shares, which is 2.2016% of the total voting shares [5] - Among them, 225 shareholders participated through online voting, representing 85,687,314 shares, which is 13.8483% of the total voting shares [5] Group 3: Voting Procedures and Results - The meeting utilized both on-site and online voting methods, with all proposed resolutions being voted on without any postponement [6] - The voting results showed that the resolutions were overwhelmingly approved, with the highest approval rate being 99.8124% for one of the proposals [6][7][8][9] - The legal opinion concludes that the voting procedures and results comply with relevant laws and regulations [10]

奥美医疗: 关于首次回购公司股份的公告 证券代码：002950 证券简称：奥美医疗 公告编号：2025-010 奥美医疗用品股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 奥美医疗用品股份有限公司（以下简称"公司"）董事会于 2025 年 1 月 20 日召开 第三届董事会第十二次会议，审议通过了《关于以集中竞价交易方式回购公司股份方 案的议案》，同意公司以自有资金及股票回购专项贷款资金通过集中竞价交易方式回购 公司股份，用于股权激励或员工持股计划。本次回购价格不超过人民币 11.00 元/股 （含），回购股份的资金总额不低于人民币 5,000 万元（含）且不超过人民币 10,000 万元（含），具体回购资金总额以实际使用的资金总额为准。回购股份的实施期限为自 公司董事会审议通过本次回购方案之日起 12 个月内。具体内容详见公司分别于 2025 年 1 月 22 日、2025 年 1 月 24 日披露于巨潮资讯网（www.cninfo.com.cn）等指定信 息披露媒体的《关于回购公司股份方案暨取得股票回购专项贷款的公告》（公告编号： 公司分别于 ...

证券代码：002950 证券简称：奥美医疗 公告编号：2025-009 截至 2025 年 2 月 28 日，本次回购公司暂未通过回购专用证券账户以集中竞价交 易方式回购公司股份。 二、其他说明 截至目前，本次回购实施情况与回购股份方案不存在差异。公司后续将根据市场 情况在回购期限内实施本次回购计划，并按照相关法律法规的规定及时履行信息披露 义务。敬请广大投资者关注后续公告，并注意投资风险。 特此公告。 奥美医疗用品股份有限公司 关于股份回购进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 奥美医疗用品股份有限公司（以下简称"公司"）董事会于 2025 年 1 月 20 日召开 第三届董事会第十二次会议，审议通过了《关于以集中竞价交易方式回购公司股份方 案的议案》，同意公司以自有资金及股票回购专项贷款资金通过集中竞价交易方式回购 公司股份，用于股权激励或员工持股计划。本次回购价格不超过人民币 11.00 元/股 （含），回购股份的资金总额不低于人民币 5,000 万元（含）且不超过人民币 10,000 万元（含），具体回购资金总额以实际使用的资金总额 ...